Pandemic preparedness, RYZ101 radiopharmaceutical trial results and Livmarli rare-disease research.
Pandemic preparedness
UN adopts new declaration on pandemic preparedness
The UN General Assembly adopted a declaration calling for stronger disease surveillance, sustainable financing and expanded regional manufacturing capacity. WHO welcomed the decision and urged countries to complete negotiations on pathogen access and benefit-sharing, a remaining step towards bringing the WHO Pandemic Agreement into force.
Why it matters: Sets priorities relevant to public-health planning, vaccine and medicine supply, and equitable access during future emergencies.
Bristol Myers Squibb reports Phase III radiopharmaceutical trial success
Bristol Myers Squibb announced that investigational RYZ101 improved progression-free survival in an interim analysis of ACTION-1. The trial enrolled patients with receptor-positive gastroenteropancreatic neuroendocrine tumours whose disease had progressed after lutetium-177 therapy; detailed results are pending, and overall-survival follow-up continues.
Why it matters: Supports further development of actinium-based targeted cancer therapies for patients with limited options, although regulatory approval remains pending.
Livmarli reduces itching in trial of ultra-rare liver diseases
Mirum reported that its 52-patient EXPAND trial met its primary endpoint, with maralixibat reducing cholestatic itching compared with placebo in the paediatric analysis. The company plans a US application for additional indications in the first half of 2027; diarrhoea occurred more frequently with treatment, at 64% versus 11.1% with placebo.
Why it matters: Provides evidence supporting a possible treatment expansion into conditions including biliary atresia, where persistent itching creates a substantial burden for children and families.
Editorial summaries for general information only; not medical advice. Research findings and company announcements should be read in their original context.